Our results from this study support the possible relevance of blocking phosphorylation of IGFBP-3 by CK2 to reverse cisplatin resistance in NSCLC cells and might lead to effective and novel therapeutic approaches to enhance the efficacy of cisplatin in NSCLC. Here, IGFBP3 is linked to non-small cell lung carcinoma.